BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38320351)

  • 21. Arsenic trioxide augments immunogenic cell death and induces cGAS-STING-IFN pathway activation in hepatocellular carcinoma.
    Li X; Pan YF; Chen YB; Wan QQ; Lin YK; Shang TY; Xu MY; Jiang TY; Pei MM; Tan YX; Dong LW; Wan XY
    Cell Death Dis; 2024 Apr; 15(4):300. PubMed ID: 38684648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A recombinant oncolytic influenza virus expressing a PD-L1 antibody induces CD8
    Sun F; Xu Y; Deng Z; Yang P
    Int Immunopharmacol; 2023 Jul; 120():110323. PubMed ID: 37207446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The miR-561-5p/CX
    Chen EB; Zhou ZJ; Xiao K; Zhu GQ; Yang Y; Wang B; Zhou SL; Chen Q; Yin D; Wang Z; Shi YH; Gao DM; Chen J; Zhao Y; Wu WZ; Fan J; Zhou J; Dai Z
    Theranostics; 2019; 9(16):4779-4794. PubMed ID: 31367257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
    Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
    Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Wnt/β-catenin inhibitor ICG-001 enhances the antitumor efficacy of radiotherapy by increasing radiation-induced DNA damage and improving tumor immune microenvironment in hepatocellular carcinoma.
    Huang Y; Sheng H; Xiao Y; Hu W; Zhang Z; Chen Y; Zhu Z; Wu D; Cao C; Sun J
    Radiother Oncol; 2021 Sep; 162():34-44. PubMed ID: 34214613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Natural Killer Cell Expansion with Autologous Feeder Layer and Anti-CD3 Antibody for Immune Cell Therapy of Hepatocellular Carcinoma.
    Hosseinzadeh F; Ai J; Ebrahimi-Barough S; Seyhoun I; Hajifathali A; Muhammadnejad S; Hosseinzadeh F; Shadnoush M; Dabiri Oskouei F; Verdi J
    Asian Pac J Cancer Prev; 2019 Dec; 20(12):3797-3803. PubMed ID: 31870124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Live cell imaging of highly activated natural killer cells against human hepatocellular carcinoma in vivo.
    Uong TNT; Yoon MS; Lee KH; Hyun H; Nam TK; Min JJ; Nguyen HPQ; Kim SK
    Cytotherapy; 2021 Sep; 23(9):799-809. PubMed ID: 34176769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trichostatin A Sensitizes Hepatocellular Carcinoma Cells to Enhanced NK Cell-mediated Killing by Regulating Immune-related Genes.
    Shin S; Kim M; Lee SJ; Park KS; Lee CH
    Cancer Genomics Proteomics; 2017; 14(5):349-362. PubMed ID: 28871002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CNOT7 depletion reverses natural killer cell resistance by modulating the tumor immune microenvironment of hepatocellular carcinoma.
    Ren C; Ren X; Cao D; Zhao H; Zhai Z; Li H; Li Y; Fu X; He J; Zhao H
    FEBS Open Bio; 2020 May; 10(5):847-860. PubMed ID: 32160402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Macrophage STING signaling promotes NK cell to suppress colorectal cancer liver metastasis via 4-1BBL/4-1BB co-stimulation.
    Sun Y; Hu H; Liu Z; Xu J; Gao Y; Zhan X; Zhou S; Zhong W; Wu D; Wang P; Rao Z; Kong L; Zhou H
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36927529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current and Future States of Natural Killer Cell-Based Immunotherapy in Hepatocellular Carcinoma.
    Nguyen T; Chen PC; Pham J; Kaur K; Raman SS; Jewett A; Chiang J
    Crit Rev Immunol; 2024; 44(5):71-85. PubMed ID: 38618730
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RECQL4 Inhibits Radiation-Induced Tumor Immune Awakening via Suppressing the cGAS-STING Pathway in Hepatocellular Carcinoma.
    Hong W; Zhang Y; Wang S; Li Z; Zheng D; Hsu S; Zhou J; Fan J; Chen Z; Xia X; Zeng Z; Gao Q; Yu M; Du S
    Adv Sci (Weinh); 2024 Apr; 11(16):e2308009. PubMed ID: 38381090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. iRGD-modified memory-like NK cells exhibit potent responses to hepatocellular carcinoma.
    Dong Y; Huang Y; Zhang Z; Chen A; Li L; Tian M; Shen J; Shao J
    J Transl Med; 2023 Mar; 21(1):205. PubMed ID: 36932395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eukaryotic elongation factor-2 kinase (eEF2K) signaling in tumor and microenvironment as a novel molecular target.
    Karakas D; Ozpolat B
    J Mol Med (Berl); 2020 Jun; 98(6):775-787. PubMed ID: 32377852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased Siglec-9/Siglec-9L interactions on NK cells predict poor HCC prognosis and present a targetable checkpoint for immunotherapy.
    Xiao R; Tian Y; Zhang J; Li N; Qi M; Liu L; Wang J; Li Z; Zhang J; Zhao F; Wang T; Tan S; Li C; Wu Z; Yu M; Jiang X; Zhan P; Gao L; Han B; Liu X; Liang X; Ma C
    J Hepatol; 2024 May; 80(5):792-804. PubMed ID: 38331327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
    Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
    J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toll-like receptor 3 expressing tumor parenchyma and infiltrating natural killer cells in hepatocellular carcinoma patients.
    Chew V; Tow C; Huang C; Bard-Chapeau E; Copeland NG; Jenkins NA; Weber A; Lim KH; Toh HC; Heikenwalder M; Ng IO; Nardin A; Abastado JP
    J Natl Cancer Inst; 2012 Dec; 104(23):1796-807. PubMed ID: 23197495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer cell-intrinsic STING is associated with CD8 + T-cell infiltration and might serve as a potential immunotherapeutic target in hepatocellular carcinoma.
    Zhang Y; Zhai Q; Feng X; Chen D; Lu Y; Hu J; Xie H; Zhou L; Wu J; Zheng S
    Clin Transl Oncol; 2021 Jul; 23(7):1314-1324. PubMed ID: 33502741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms and network pharmacological analysis of Yangyin Fuzheng Jiedu prescription in the treatment of hepatocellular carcinoma.
    Xie Y; Yan F; Wang X; Yu L; Yan H; Pu Q; Li W; Yang Z
    Cancer Med; 2023 Feb; 12(3):3237-3259. PubMed ID: 36043445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.